Sign In
Buy GSK
$51.46
-0.0700 (-0.136%)
At Close: Aug 05, 2026
GSK boss sees pay jump 51% in 2023
10:53am, Friday, 01'st Mar 2024
GSK PLC (LSE:GSK, NYSE:GSK) boss Emma Walmsley saw her overall pay rise 51% to around £13 million in 2023 after she received a large hike in performance-related bonuses. Some £11 million of the pay
GSK (GSK) Stock Declines While Market Improves: Some Information for Investors
07:01pm, Thursday, 29'th Feb 2024
In the most recent trading session, GSK (GSK) closed at $41.90, indicating a -1.04% shift from the previous trading day.
Investors Heavily Search GSK PLC Sponsored ADR (GSK): Here is What You Need to Know
10:01am, Thursday, 29'th Feb 2024
Zacks.com users have recently been watching Glaxo (GSK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
GSK settles another California lawsuit
03:31am, Thursday, 29'th Feb 2024
GSK PLC (LSE:GSK, NYSE:GSK) has confidentially settled a lawsuit in California that claimed its now-discontinued heartburn medication, Zantac, caused cancer. This agreement, ahead of a trial schedule
GSK settles another lawsuit on heartburn drug Zantac in California
02:24am, Thursday, 29'th Feb 2024
GSK agreed to confidentially settle another lawsuit in California that had alleged its discontinued heartburn drug Zantac caused cancer, the latest in a series of settlements made by the British drugm
Here's Why GSK (GSK) is a Strong Momentum Stock
10:56am, Wednesday, 28'th Feb 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why GSK (GSK) is a Strong Value Stock
10:46am, Tuesday, 27'th Feb 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
All You Need to Know About Glaxo (GSK) Rating Upgrade to Buy
01:00pm, Monday, 26'th Feb 2024
Glaxo (GSK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
GSK meets main endpoint in oral gonorrhea treatment trial
11:00am, Monday, 26'th Feb 2024
GSK has hailed the results from a late-stage trial of a new oral antibiotic for gonorrhoea, which met its primary endpoint of at last matching the current standard treatments. Chris Corsico, senior vi
Are Medical Stocks Lagging GSK PLC Sponsored ADR (GSK) This Year?
10:46am, Monday, 26'th Feb 2024
Here is how GSK (GSK) and Akero Therapeutics, Inc. (AKRO) have performed compared to their sector so far this year.
GSK's gonorrhoea drug meets primary goal in late-stage trial
02:03am, Monday, 26'th Feb 2024
British drugmaker GSK said on Monday its oral gonorrhoea drug met its primary goal of non-inferiority in a late-stage trial, compared to an existing combination treatment.
This pharma stock surged 13% in a day
04:14am, Friday, 23'rd Feb 2024
Moderna (NASDAQ: MRNA) stock significantly surged on February 22 after the company surpassed Wall Street's quarterly expectations.
3 Low-Priced Dividend Stocks With Solid Fundamentals & Growth
02:00pm, Wednesday, 21'st Feb 2024
Good dividend stocks provide their owners with reliable income. What's more, even if these equities drop, investors are “paid to wait” for them to rebound down the road.
First Long-Acting Injectable HIV Treatment Works Better Than Daily Pills For Some Patients, GSK Says
06:21am, Wednesday, 21'st Feb 2024
British pharma giant GSK on Wednesday announced promising results for a long-acting injectable HIV therapy, offering a hopeful alternative for people who take daily pills to halt the virus's progressi
GSK's injectable HIV drug shows promise over daily pills
03:17am, Wednesday, 21'st Feb 2024
British drugmaker GSK said on Wednesday its long-acting injectable HIV therapy showed promise in keeping the viral load suppressed compared to daily oral treatment, especially in individuals facing ch
